UCB Announces Major Investment to Expand US Biologics Manufacturing Capacity
UCB, a global biopharmaceutical company, has announced a substantial investment in a new, state-of-the-art biologics manufacturing facility in the United States413.
The exact location of the new facility has not yet been determined; a feasibility study is underway5.
The facility is expected to generate an estimated total economic impact of approximately $5 billion over its life243.
About 300 permanent, highly skilled direct jobs in biologics manufacturing will be created, along with more than 500 jobs during the construction phase245.
This expansion is part of UCB's broader commitment to scientific innovation, sustainable healthcare, and strengthening its supply chain resilience in the US34.
UCB will also deepen its partnerships with US-based Contract Manufacturing Organizations (CMOs) to support its product pipeline and growth drivers45.
Since 2017, UCB's US workforce has grown by 73% to approximately 2,000 employees, supported by $4.5 billion in acquisitions and capital investments, and 15 US FDA approvals since 20175.
Sources:
1. https://firstwordpharma.com/story/5972630
2. https://www.nasdaq.com/articles/ucb-invest-us-biologics-facility-5-bln-economic-impact
3. https://www.fiercepharma.com/manufacturing/ucb-touts-plan-major-us-investment-boost-biologics-capacity
4. https://www.ucb.com/newsroom/press-releases/article/ucb-announces-major-us-investment-to-expand-biologics-manufacturing-capacity
5. https://www.dcatvci.org/top-industry-news/ucb-investing-in-new-us-biomanufacturing-facility/